Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Registration Number
- NCT00346827
- Lead Sponsor
- Britannia Pharmaceuticals Ltd.
- Brief Summary
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day
Exclusion Criteria
- hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method